Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Tempest Therapeutics Shares Up 19% Premarket. A Press Release Earlier Announced A Presentation On Its Liver Cancer Treatment At ASCO Annual Meeting 2024

Author: Charles Gross | January 30, 2024 07:51am

Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics, today announced its participation in the American Society of Clinical Oncology (ASCO) Annual Meeting 2024. The company presented compelling data highlighting the efficacy and safety of its lead candidate, TPST-1120, a first-in-class PPARα antagonist, in the treatment of liver cancer and other malignancies.

Posted In: TPST


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist